Stock 300584 NANJING HICIN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Nanjing Hicin Pharmaceutical Co., Ltd.

Equities

300584

CNE100002F44

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 12/05/2024 BST 		5-day change 1st Jan Change
18.54 CNY +0.27% Intraday chart for Nanjing Hicin Pharmaceutical Co., Ltd. +0.82% -20.36%
04-25 Nanjing Hicin Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2023 CI
04-24 Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,897 3,379 2,462 2,400 3,864 2,794
Enterprise Value (EV) 1 2,896 3,353 2,519 2,465 3,947 3,018
P/E ratio 34.8 x 34.7 x 44.6 x 8.4 x 119 x 76.9 x
Yield 0.83% 0.89% 0.61% 1.25% - 0.21%
Capitalization / Revenue 4.07 x 3.66 x 3.49 x 4.15 x 7.34 x 5.39 x
EV / Revenue 4.07 x 3.63 x 3.57 x 4.26 x 7.5 x 5.83 x
EV / EBITDA 25.3 x 23.2 x 26 x 37.2 x 47.8 x 31.1 x
EV / FCF -131 x 83.7 x -35.7 x 115 x -16.9 x -16.9 x
FCF Yield -0.77% 1.2% -2.8% 0.87% -5.9% -5.91%
Price to Book 4.99 x 5.17 x 3.62 x 2.53 x 4.06 x 2.83 x
Nbr of stocks (in thousands) 120,000 120,000 120,000 120,000 120,000 120,000
Reference price 2 24.14 28.16 20.52 20.00 32.20 23.28
Announcement Date 01/04/19 08/04/20 07/04/21 21/04/22 24/04/23 24/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 711.9 924.5 706.3 578.3 526.5 517.8
EBITDA 1 114.3 144.8 96.99 66.26 82.56 96.97
EBIT 1 97.59 117.2 65.59 29.41 34.63 43.52
Operating Margin 13.71% 12.67% 9.29% 5.09% 6.58% 8.4%
Earnings before Tax (EBT) 1 95.97 114.2 61.35 330.4 28.78 37.69
Net income 1 83.22 97.26 55.23 285.9 32.45 36.32
Net margin 11.69% 10.52% 7.82% 49.43% 6.16% 7.01%
EPS 2 0.6935 0.8105 0.4603 2.382 0.2704 0.3026
Free Cash Flow 1 -22.16 40.09 -70.62 21.51 -232.9 -178.4
FCF margin -3.11% 4.34% -10% 3.72% -44.24% -34.46%
FCF Conversion (EBITDA) - 27.69% - 32.46% - -
FCF Conversion (Net income) - 41.22% - 7.52% - -
Dividend per Share 2 0.2000 0.2500 0.1250 0.2500 - 0.0500
Announcement Date 01/04/19 08/04/20 07/04/21 21/04/22 24/04/23 24/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 57 64.7 83.1 224
Net Cash position 1 1.27 25.9 - - - -
Leverage (Debt/EBITDA) - - 0.5873 x 0.9762 x 1.006 x 2.312 x
Free Cash Flow 1 -22.2 40.1 -70.6 21.5 -233 -178
ROE (net income / shareholders' equity) 15.2% 15.7% 8.18% 35% 3.38% 3.75%
ROA (Net income/ Total Assets) 8.55% 8.8% 4.62% 1.66% 1.67% 2.01%
Assets 1 973.2 1,105 1,196 17,174 1,946 1,804
Book Value Per Share 2 4.840 5.450 5.660 7.920 7.920 8.230
Cash Flow per Share 2 0.8400 1.250 0.8600 0.9600 0.7900 0.3900
Capex 1 76.7 43.4 120 94.4 219 197
Capex / Sales 10.77% 4.69% 17% 16.33% 41.59% 38.09%
Announcement Date 01/04/19 08/04/20 07/04/21 21/04/22 24/04/23 24/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NANJING HICIN PHARMACEUTICAL CO., LTD. Stock Nanjing Hicin Pharmaceutical Co., Ltd.
-20.36% 307M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.98% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.34% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.52% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.59% 329B
ABBVIE INC. Stock AbbVie Inc.
+4.07% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.21% 240B
NOVARTIS AG Stock Novartis AG
+9.66% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-6.83% 200B
AMGEN INC. Stock Amgen Inc.
+7.09% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300584 Stock
  4. Financials Nanjing Hicin Pharmaceutical Co., Ltd.